Top Markets
#1 Helium Helium +49.84%
#2 TENDIES TENDIES +37.70%
#3 Pons Pons +29.59%
#4 Seeker Seeker +20.73%
#5 UnifAI Network UnifAI Network +15.18%
#6 pipedog pipedog +13.53%
#7 Songbird Songbird +12.18%
#8 StonkBroker StonkBroker +11.81%
#9 OSK OSK +9.95%
#10 Lista DAO Lista DAO +9.95%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Rank in Stocks #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Share Price
$14.66
Last synced: 2026-08-28
Market Cap
$839.37M
Change (1 day)
-2.67%
Change (1 year)
557.32%
Country
US
Trade Climb Bio, Inc. (CLYM)

Category

Healthcare
Revenue for Climb Bio, Inc. (CLYM)
Revenue in Aug 2026 TTM: 0
According to Climb Bio, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Climb Bio, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH